Posted on 10/12/18
Verastem Oncology Prices Registered Direct Offering of $150 Million of Convertible Notes
BOSTON--(BUSINESS WIRE)--Verastem, Inc., (Nasdaq: VSTM), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the pricing . . .
Posted on 10/12/18
Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes
NEWTON, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of $150 million aggregate principal amount . . .
Posted on 10/11/18
Intermountain Healthcare Partners with Grand Rounds
Grand Rounds, the leader in matching patients with high-quality physicians, and leading health system Intermountain Healthcare, today announced a strategic agreement which will enhance Intermountain's world-class . . .
Posted on 10/11/18
JAC Partners with TraceLink
TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today . . .
Posted on 10/11/18
MEI Pharma and BeiGene Announce Clinical Collaboration
MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical . . .
Posted on 10/11/18
Histogenics Corp. Closes Public Offering of Common Stock and Warrants
WALTHAM, Mass., Oct. 10, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies, today announced the closing . . .
Posted on 10/11/18
CVS Health Provides Update to Board and Management Roles Upon Closing of Aetna Acquisition
CVS Health (NYSE: CVS) today announced that three additional Aetna directors with deep insurance company oversight experience -- Edward J. Ludwig, Fernando Aguirre, and Roger N. . . .
Posted on 10/10/18
NanoView Completes $10 Million Series B Financing
NanoView Biosciences, an emerging leader in the field of exosome detection and characterization, today announced the closing of a $10 million Series B financing
Posted on 10/10/18
Cara Therapeutics Inks Distribution Deal, Stock Will Push Higher
SummaryCara Therapeutics just entered critical stage III testing with its key drug Korsuva.A German company paid $50 million for rights to distribute what could be a . . .
Posted on 10/10/18
Neurocrine Biosciences and Jnana Therapeutics Enter Strategic Collaboration
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at discovering novel small molecule therapeutics . . .
Posted on 10/9/18
Biohaven Acquires Option To License Biologic Investigational Agent For Inflammatory And Autoimmune Diseases From The University of Connecticut
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it signed an exclusive, worldwide option and license agreement with the University of Connecticut for the . . .
Posted on 10/9/18
Glympse Bio Raises $22M Series A Financing
Glympse Bio, Inc. announced today that it has raised $22 million in Series A funding. The proceeds of this round will be devoted to conducting clinical . . .
Posted on 10/9/18
Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline
Innovation Pharmaceuticals, (OTCQB:IPIX), a clinical stage biopharmaceutical company, is pleased to report that it has secured new financing for up to $10 million
Posted on 10/9/18
Raytheon Is One Of The Cheapest Defense Stocks - Cramer's Lightning Round (10/4/18)
Nektar Therapeutics (NASDAQ:NKTR): "I think it's a great spec. It's got a big pipeline of drugs. You know, look, the speculative stocks aren't working that well . . .
Posted on 10/9/18
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced that on October . . .
Posted on 10/9/18
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, . . .
Posted on 10/9/18
Epizyme Announces Closing of Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the closing of its underwritten public offering of 9,583,334 shares of . . .
Posted on 10/5/18
T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical . . .
Posted on 10/4/18
Medrobotics Announces First Sale of Flex Robotic System in Europe for Gastroenterology Applications
RAYNHAM, Mass.--(BUSINESS WIRE)--Medrobotics Corp. today announced the first sale in Europe of their Flex Robotic System for gastroenterology applications. The hospital, A.O. Universitaria Città della Salute . . .
Posted on 10/4/18
Agilent To Acquire ACEA Biosciences For Cell Analysis Technologies
SummaryAgilent Technologies has agreed to acquire ACEA Biosciences for an undisclosed amount.ACEA makes a range of real-time cell analysis and cytometer products, software, and consummables for . . .
Posted on 10/4/18
RXi Pharmaceuticals Closes $15 Million Underwritten Public Offering
RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, today announced . . .
Posted on 10/3/18
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on October 1, . . .
Posted on 10/3/18
Kala Pharmaceuticals Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, announced today the . . .
Posted on 10/3/18
Buoy Health Receives Robert Wood Johnson Foundation Artificial Intelligence Award for Patient Health Education
BOSTON--(BUSINESS WIRE)--Buoy Health,an AI health assistant that helps people from the moment they get sick start their care on the right foot, today announced they were . . .
Posted on 10/3/18
Boston Pharmaceuticals Acquires Three Novel Anti-Infective Programs from Novartis
Boston Pharmaceuticals Inc. (Boston Pharmaceuticals) today announced a licensing and equity agreement with Novartis through which Boston Pharmaceuticals

